Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from Keros ...

In other recent news, Keros Therapeutics, Inc. has announced agreements to repurchase shares from ADAR1 Capital Management and Pontifax Venture Capital for a total of approximately $181 million. This ...

Keros, a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to transforming growth factor-beta protein signaling, stated it continues to target a first ...

LEXINGTON, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

While not a mind-blowing move, it is good to see that the Keros Therapeutics, Inc. (NASDAQ:KROS) share price has gained 12% in the last three months. But that isn't much consolation for the painful ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Keros Therapeutics ( (KROS)) has provided ...

LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

Keros Therapeutics, Inc. faces uncertainty after discontinuing its lead asset, with current value driven mainly by a strong cash position and pipeline potential. KER-065 received FDA Orphan Drug ...

Keros Therapeutics has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy (DMD ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...